½ÃÀ庸°í¼­
»óǰÄÚµå
1682220

ÀÇ»ç ¼³¹®Á¶»ç : AI°¡ ¾Ï Ä¡·áÀÇ ¹Ì·¡¸¦ Çü¼ºÇÒ °ÍÀ¸·Î º¸°í ÀÖ½À´Ï´Ù.Á¾¾çÇÐÀÚµé

Physician Poll: Oncologists See AI Shaping the Future of Cancer Treatment

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: FirstWord Group | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¾Ï Ä¡·áÀÇ ¹ßÀü¿¡ ±â¿©ÇÏ´Â AI´Â »ç¶÷º¸´Ù ´õ ºü¸£°í Á¤È®ÇÏ°Ô ÀÇ·á ¿µ»óÀ» ºÐ¼®ÇÏ¿© ¹ß°ß°ú Áø´ÜÀ» ºü¸£°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ³ôÀº Á¤È®µµ¸¦ ÅëÇØ AI´Â ¿ÀÁøÀ» ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. AI´Â À¯Àüü µ¥ÀÌÅÍ ºÐ¼®À» ÅëÇØ Ä¡·á È¿°ú¸¦ ¿¹ÃøÇÔÀ¸·Î½á ¾Ï Ä¡·áÀÇ °³ÀÎÈ­¸¦ µ½½À´Ï´Ù.

µö·¯´×Àº ÆÐÅÏ ÀÎ½Ä ´É·ÂÀ» Áö¼ÓÀûÀ¸·Î Çâ»ó½ÃÅ´À¸·Î½á ¾Ç¼º Á¾¾ç°ú ¾ç¼º Á¾¾çÀ» º¸´Ù Á¤È®ÇÏ°Ô ±¸ºÐÇÒ ¼ö ÀÖ°Ô µÇ¾î ¾Ï °¨Áö¸¦ ´õ¿í °­È­ÇÒ ¼ö ÀÖ½À´Ï´Ù.

º» º¸°í¼­´Â ¹Ì±¹°ú À¯·´ 5°³±¹(ÇÁ¶û½º, µ¶ÀÏ, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ¿µ±¹)¿¡ °ÅÁÖÇÏ´Â 192¸íÀÇ Á¾¾ç Àü¹®ÀǵéÀ» ´ë»óÀ¸·Î ¾Ï Áø´Ü ¹× Ä¡·á °èȹ¿¡¼­ AI ¾Ë°í¸®ÁòÀÇ ÇöÀç ¹× ¹Ì·¡ µµÀÔ ¼öÁØÀ» Æò°¡Çϱâ À§ÇØ ¼³¹®Á¶»ç¸¦ ½Ç½ÃÇß½À´Ï´Ù.

º¸°í¼­ ³»¿ë

  • AI¸¦ À̹ÌÁö ºÐ¼®¿¡ Àû¿ëÇÏ¸é ´Ù¾çÇÑ À¯ÇüÀÇ ¾ÏÀÇ °ËÃâ°ú ºÐ·ù¸¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÇöÀç ¾Ï Áø´ÜÀ» À§ÇÑ ¿µ»ó ÆÇµ¶¿¡ AI ¼ÒÇÁÆ®¿þ¾î¸¦ ¾î´À Á¤µµ »ç¿ëÇϰí Àִ°¡?
  • 5³â ÈÄ, AI¸¦ ÀÌ¿ëÇÑ ¿µ»óºÐ¼®À¸·Î ȯÀÚÀÇ ¾Ï Áø´Ü ¼Óµµ°¡ Å©°Ô Çâ»óµÉ °ÍÀ̶ó´Â °Í¿¡ ¾î´À Á¤µµ µ¿ÀÇÇϴ°¡?
  • µö·¯´× AI´Â Áúº´ÀÇ ÁøÇàÀ» ¿¹ÃøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÇöÀç ȯÀÚ Ä¡·á ÇÁ·Î±×·¥À» °èȹÇÒ ¶§ ȯÀÚº° À§Çè¿äÀÎÀ» ÃßÁ¤Çϱâ À§ÇØ µö·¯´× AI¸¦ ¾î´À Á¤µµ Ȱ¿ëÇϰí Àִ°¡?
  • AI ¾Ë°í¸®ÁòÀº À¯ÀüÀû Ç×¾ÏÁ¦ °¨¼ö¼ºÀ» È®ÀÎÇϱâ À§ÇÑ À¯Àüü °Ë»ç¿¡µµ Àû¿ëµÉ ¼ö ÀÖ½À´Ï´Ù. ÇöÀç ȯÀÚ ¸ÂÃãÇü Ä¡·á °èȹÀ» ¼ö¸³Çϱâ À§ÇØ AI ±â¹Ý ÀÓ»ó ÀÇ»ç°áÁ¤ Áö¿ø µµ±¸¸¦ ¾î´À Á¤µµ Ȱ¿ëÇϰí Àִ°¡?
  • ÇâÈÄ 5³â°£ AI°¡ ȯÀÚ Ä¡·á °èȹ¿¡ Çõ¸íÀ» °¡Á®¿Ã °ÍÀ̶ó´Â µ¥ ¾î´À Á¤µµ µ¿ÀÇÇϴ°¡?
LSH 25.03.31

The backstory

Helping to advance cancer treatment, AI speeds up detection and diagnosis by analysing medical images faster and with more precision than can be done by humans. In addition, its greater accuracy allows AI to minimise false-positive diagnoses. Through the analysis of genomic data, AI helps personalise oncology care by predicting treatment response.

Deep learning further enhances cancer detection by continuously improving its pattern recognition capabilities, which allows it to more precisely distinguish malignant tumours from benign ones.

The physician view

FirstWord polled 192 oncologists based in the US and EUR5 (France, Germany, Italy, Spain and the UK) to assess current and future adoption levels of AI algorithms in cancer diagnosis and treatment planning.

Key Questions Answered:

  • 1. AI can be applied to image analysis to improve detection and classification of different types of cancer. How often do you currently use AI software to help with interpreting images for cancer diagnosis?
  • 2. Thinking ahead, how much do you agree that AI-based image analysis will significantly improve the speed of cancer diagnosis for your patients in five years' time?
  • 3. Deep learning AI can predict disease progression. To what extent are you currently utilising deep learning AI to estimate patient-specific risk factors when planning treatment programmes for your patients?
  • 4. AI algorithms can also be applied to genomic testing to identify genetic anticancer drug susceptibility. To what extent are you currently using AI-based clinical decision support tools to develop personalised treatment plans for your patients?
  • 5. To what extent do you agree that AI will revolutionise treatment planning for your patients over the next five years?

Methodology

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦